BackInsmed Overview
Insmed Inc

Insmed Target Price

Analysts' average 12-month price target for Insmed is $190.

Get informed when a big investor buys or sells

+ Follow

Share Price

$126.33

Average Target Price

$194.0053.6% upside

15 analysts in the last 4 months

High: $235 | Low: $160

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-07Morgan Stanley$21872.6% upsideOpen
2026-08-07Evercore ISI$17034.6% upsideOpen
2026-08-07Guggenheim$20562.3% upsideOpen
2026-08-07UBS$17236.2% upsideOpen
2026-08-07Wells Fargo$16933.8% upsideOpen
2026-08-06Jefferies$17538.5% upsideOpen
2026-07-28Cantor FitzgeraldOlivia Brayer$23586% upsideOpen
2026-07-20BMO CapitalConor MacKay$19252% upsideOpen
2026-07-20H.C. WainwrightAndrew Fein$22074.1% upsideOpen
2026-07-15Wells Fargo$16127.4% upsideOpen
2026-06-16Mizuho SecuritiesGraig Suvannavejh$19252% upsideOpen
2026-05-13Truist Financial$18546.4% upsideOpen
2026-05-08Wells Fargo$16026.7% upsideOpen
2026-05-08GuggenheimVamil Divan$22678.9% upsideOpen
2026-04-16Guggenheim$23082.1% upsideOpen
2026-04-14RBC Capital$21671% upsideOpen
2026-04-10Raymond James$20058.3% upsideOpen
2026-04-08Mizuho Securities$20259.9% upsideOpen
2026-03-26H.C. Wainwright$24593.9% upsideOpen
2026-02-24Mizuho Securities$20461.5% upsideOpen
2026-02-20Morgan Stanley$16631.4% upsideOpen
2026-02-20Wells FargoTiago Fauth$20864.6% upsideOpen
2026-02-19Stifel Nicolaus$20562.3% upsideOpen
2026-02-19Mizuho SecuritiesGraig Suvannavejh$21167% upsideOpen
2026-01-27BarclaysEliana Merle$23182.9% upsideOpen
2026-01-22Roth Capital$21267.8% upsideOpen
2026-01-21RBC CapitalLeonid Timashev$20058.3% upsideOpen
2026-01-12Truist FinancialDanielle Brill$20562.3% upsideOpen
2026-01-08Morgan StanleyMaxwell Skor$15724.3% upsideOpen
2026-01-06UBS$21570.2% upsideOpen
2025-12-19Truist FinancialDanielle Brill$20259.9% upsideOpen
2025-12-18H.C. Wainwright$23082.1% upsideOpen
2025-12-18Cowen & Co.$24190.8% upsideOpen
2025-12-18Mizuho SecuritiesGraig Suvannavejh$21267.8% upsideOpen
2025-12-18Guggenheim$22174.9% upsideOpen
2025-12-18Wedbush$20360.7% upsideOpen
2025-12-18RBC CapitalLeonid Timashev$19554.4% upsideOpen
2025-12-18Wells Fargo$19554.4% upsideOpen
2025-12-18Wolfe ResearchAndy Chen$16732.2% upsideOpen
2025-12-16Wells FargoTiago Fauth$23485.2% upsideOpen
2025-12-16Cantor FitzgeraldOlivia Brayer$23082.1% upsideOpen
2025-12-10Jefferies$269112.9% upsideOpen
2025-12-04Redburn Partners$263108.2% upsideOpen
2025-12-01Mizuho SecuritiesGraig Suvannavejh$256102.6% upsideOpen
2025-10-31Goldman Sachs$22578.1% upsideOpen
2025-10-31RBC CapitalLeonid Timashev$21570.2% upsideOpen
2025-10-31UBSTrung Huynh$22376.5% upsideOpen
2025-10-31Wells Fargo$21771.8% upsideOpen
2025-10-29Mizuho SecuritiesGraig Suvannavejh$19655.1% upsideOpen
2025-10-28Cantor Fitzgerald$19252% upsideOpen

Insmed (INSM) FAQ

Insmed's target price stands at $190. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $190 for INSM implies 53.6% upside versus today's price ($126.33). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Insmed's target price evolved across reporting periods, while the comparison chart places INSM next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Insmed's reading of $190 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.